A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (ZEN)

  • STATUS
    Recruiting
  • End date
    Jul 17, 2026
  • participants needed
    156
  • sponsor
    Sanofi
Send
Updated on 9 May 2025
See if I qualify

Summary

This is a parallel, Phase 2, 3-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years.

Study details include:

  • Screening period: up to 4 weeks (30 days)
  • Treatment duration: up to 16 weeks
  • Follow-up period: up to 4 weeks
  • Total study duration: up to 24 weeks
  • Number of visits: 14

Details
Condition Hidradenitis Suppurativa
Age 18years - 70years
Clinical Study IdentifierNCT06028230
SponsorSanofi
Last Modified on9 May 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participant with a history of signs and symptoms consistent with HS for at least 1 year prior to baseline
Participant must have HS lesions present in at least 2 distinct anatomic areas, one of which must be Hurley Stage II or Hurley Stage III
Participant must have had an inadequate response after at least one-month of oral antibiotic treatment for HS, as assessed by the Investigator
Participant must have a total AN count of ≥5 at the baseline visit
Participant must have a draining tunnel count of ≤20 at the baseline visit
Participant must be willing and able to complete the diary for the duration of the study as required by the study protocol
Contraceptive use by men with a partner of childbearing potential and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Exclusion Criteria

Participant with any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS
Any active or chronic infection requiring systemic treatment (eg, antibiotics, antivirals, antifungals, antihelminthics) within 30 days prior to baseline
Known history of or suspected significant suppressed immune response, including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration
Participant with history of solid organ transplant
Participant with history of splenectomy
Participant with history of any malignancy or lymphoproliferative disease, except if the participant has been free from disease for ≥5 years. Successfully treated non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix are allowed
Participant with a diagnosis of chronic immune-mediated, inflammatory conditions other than HS
Participant with family history of sudden death or long QT syndrome
Participant with history of congenital or drug-induced long QT syndrome
Participant with congestive heart failure (New York Heart Association Class 2 to 4), greater than Class 1 angina pectoris, acute coronary syndrome within prior 6 months, known structural heart disease
Participant with history of any major cardiovascular events (eg, myocardial infarction, unstable angina pectoris, coronary revascularization, stroke, or transient ischemic attack) at any time prior to screening
Participant with history of ventricular fibrillation, ventricular tachycardia, torsades de pointes, atrial fibrillation, syncope not explained by non-cardiac etiology
Participant with uncontrolled hypertension defined as consistent systolic blood pressure ≥150 mmHg or consistent diastolic blood pressure ≥90 mmHg despite antihypertensive medication
Participant received prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit
Prior or active treatment with any systemic biologic (anti-TNF) therapy, anti-IL17 therapy, anti-IL1/anti-IL1 receptor therapy except for up to 20% of the total study population. Furthermore, this 20% of biologic-experienced participants must fulfilled one or more of the following conditions
Discontinued due to treatment related toxicity and/or
Discontinuation is not related to lack or loss of therapeutic response
The above information is not intended to contain all considerations relevant
to a participant's potential participation in a clinical trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.